SC
TERN

Stempoint Capital’s Terns Pharmaceuticals TERN Stock Holding History

Stempoint Capital’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-429,198
Closed -$17.6M – 113
2025
Q4 		$17.3M Buy
429,198
+339,581
+379% +$7.85M 2.97% 8
2025
Q3 		$673K Buy
+89,617
New +$572K 0.13% 73
2024
Q4 		– Sell
-449,321
Closed -$3.75M – 76
2024
Q3 		$3.75M Buy
+449,321
New +$3.7M 1.12% 27

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Stempoint Capital's TERN Position: Q1 2026 in Review

Stempoint Capital sold out of Terns Pharmaceuticals (TERN) in Q1 2026, closing a stake of 429,198 shares — an estimated $17.6M sold.

Stempoint Capital first reported a position in TERN in Q3 2024 and held it in 3 quarters. The position peaked at $17.3M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Stempoint Capital reported no remaining Terns Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Stempoint Capital sold 429,198 Terns Pharmaceuticals shares in Q1 2026, an estimated $17.6M.
  • Stempoint Capital first reported a position in Terns Pharmaceuticals in Q3 2024 and held it in 3 quarters.
  • Stempoint Capital's Terns Pharmaceuticals position peaked at $17.3M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.